Sapporo Clinical Laboratory Center, Inc. (9776) AI Stock Analysis

• Market Cap: ¥3.68B
• Dividend Yield: 2.17%
• Average Volume (3M): 1.59K
• Price to Earnings (P/E): 7.4
• Beta (1Y): 0.26
• Revenue Growth: 2.23%
• EPS Growth: 12.02%
• Country: JP
• Employees: 871
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 31.13
• Shares Outstanding: 4,216,000
• 10 Day Avg. Volume: 1,420
• 30 Day Avg. Volume: 1,586
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,119.00
• Price Target Upside: 5.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 74 Outperform
• Price Target: ¥1,119.00 ▲(5.67% Upside)

Sapporo Clinical Laboratory Center, Inc. is well-positioned with strong financial performance and attractive valuation, making it an appealing investment. The technical analysis suggests moderate strength, with a need for attention to capital management to sustain cash flow. Overall, the company’s stable financial health and appealing valuation are key strengths.

Sapporo Clinical Laboratory Center, Inc. Business Overview & Revenue Model

Company Description

Sapporo Clinical Laboratory Center, Inc. (9776) is a Japanese company that operates in the healthcare sector, primarily focusing on providing clinical laboratory testing and diagnostic services. The company offers a range of services that include routine clinical tests, specialized diagnostic analyses, and health screening programs to hospitals, clinics, and other medical institutions. By leveraging advanced technology and expertise, the company aims to deliver accurate and timely diagnostic information to support patient care and medical decision-making.

How the Company Makes Money

Sapporo Clinical Laboratory Center, Inc. generates revenue primarily through the provision of clinical laboratory testing and diagnostic services. Key revenue streams include fees charged for individual laboratory tests conducted, contractual agreements with healthcare institutions for regular testing services, and health screening programs offered to corporate clients and healthcare providers. The company may also partner with hospitals and medical facilities to provide bundled diagnostic services, enhancing its service offerings and expanding its client base. Additionally, advancements in technology and healthcare trends can contribute to the company's earnings by increasing the demand for more comprehensive and specialized diagnostic tests.

Sapporo Clinical Laboratory Center, Inc. Financial Statement Overview

Summary

Sapporo Clinical Laboratory Center, Inc. exhibits a strong financial profile with consistent revenue growth and solid operational efficiency. The balance sheet is robust, indicating financial stability and prudent leverage. However, attention to capital expenditures is needed to enhance free cash flow sustainability.

Income Statement

Sapporo Clinical Laboratory Center, Inc. has demonstrated consistent revenue growth over the years, with a notable increase in EBIT and EBITDA margins, indicating solid operational efficiency. However, the net profit margin has fluctuated, reflecting some challenges in cost management or external factors impacting net income.

Balance Sheet

The company maintains a strong equity position with a favorable debt-to-equity ratio, indicating prudent financial leverage. The equity ratio is robust, showcasing stability and a solid asset base. Return on Equity has been stable, suggesting effective use of shareholder funds.

Cash Flow

Operating cash flows remain positive, yet there is volatility in free cash flow due to high capital expenditures. The company has shown resilience in generating cash flow from operations, but consistent negative free cash flow suggests the need for careful capital management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.13B	20.13B	19.68B	20.13B	19.11B	17.50B
Gross Profit	6.14B	5.95B	5.90B	6.30B	6.32B	5.73B
EBITDA	1.27B	1.27B	1.14B	1.49B	2.06B	1.45B
Net Income	464.03M	464.18M	380.16M	568.62M	1.04B	793.69M
Balance Sheet
Total Assets	16.45B	16.45B	16.68B	16.52B	16.15B	14.51B
Cash, Cash Equivalents and Short-Term Investments	2.94B	2.94B	3.98B	3.66B	2.99B	2.36B
Total Debt	1.93B	1.93B	2.20B	2.43B	2.58B	2.10B
Total Liabilities	5.06B	5.06B	5.50B	5.64B	5.81B	5.24B
Stockholders Equity	11.15B	11.15B	10.94B	10.59B	10.11B	9.27B
Cash Flow
Free Cash Flow	0.00	-491.26M	629.92M	604.44M	625.26M	-2.32B
Operating Cash Flow	0.00	730.91M	1.08B	1.43B	1.57B	837.59M
Investing Cash Flow	0.00	-1.24B	-395.47M	-409.03M	-830.96M	-3.15B
Financing Cash Flow	0.00	-525.74M	-369.96M	-347.89M	-112.74M	1.94B

Sapporo Clinical Laboratory Center, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1059.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9776, the sentiment is Neutral. The current price of 1059 is below the 20-day moving average (MA) of 1064.75, above the 50-day MA of 1039.58, and above the 200-day MA of 990.42, indicating a neutral trend. The MACD of 9.49 indicates Positive momentum. The RSI at 50.85 is Neutral, neither overbought nor oversold. The STOCH value of 73.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:9776.

Sapporo Clinical Laboratory Center, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9776	74 Outperform	¥3.68B	7.40		2.17%	2.23%	12.02%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
BMZ	―	€802.40M	20.01	5.29%	―	―	―
MRCHF	―	$1.34B	156.98	0.95%	4.15%	―	―
2395	75 Outperform	¥69.36B	13.49		3.00%	27.28%	18.29%
4671	67 Neutral	¥24.86B	13.12		4.94%	1.01%	13.91%
2385	43 Neutral	¥5.15B	―		2.62%	-6.01%	68.18%